In yesterday’s Wall Street session, Masimo Corporation (NASDAQ:MASI) shares traded at $113.59, down -0.60% from the previous session.
As of this writing, 8 analysts cover Masimo Corporation (NASDAQ:MASI). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $150.00 and a low of $110.00, we find $136.50. Given the previous closing price of $114.28, this indicates a potential upside of 19.44 percent. MASI stock price is now -12.34% away from the 50-day moving average and -27.37% away from the 200-day moving average. The market capitalization of the company currently stands at $6.04B.
There are 3 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $130.63 as their price target over the next twelve months.
With the price target reduced from $205 to $120, Stifel Downgraded its rating from Buy to Hold for Masimo Corporation (NASDAQ: MASI).
In other news, KIANI JOE E, CEO and Chairman of the Board bought 6,365 shares of the company’s stock on May 25. The stock was bought for $1,000,342 at an average price of $157.16. Upon completion of the transaction, the CEO and Chairman of the Board now directly owns 366,055 shares in the company, valued at $41.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 15, CEO and Chairman of the Board KIANI JOE E bought 7,040 shares of the business’s stock. A total of $1,019,352 was incurred on buying the stock at an average price of $144.79. This leaves the insider owning 46,818 shares of the company worth $5.32 million. Insiders disposed of 82,450 shares of company stock worth roughly $9.37 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MASI stock. A new stake in Masimo Corporation shares was purchased by WESTFIELD CAPITAL MANAGEMENT CO LP during the first quarter worth $108,342,000. JACKSON SQUARE PARTNERS, LLC invested $14,374,000 in shares of MASI during the first quarter. In the first quarter, PUTNAM INVESTMENTS LLC acquired a new stake in Masimo Corporation valued at approximately $6,997,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in MASI for approximately $4,450,000. 13D MANAGEMENT LLC purchased a new stake in MASI valued at around $3,135,000 in the second quarter. In total, there are 639 active investors with 90.50% ownership of the company’s stock.
Friday morning saw Masimo Corporation (NASDAQ: MASI) opened at $115.49. During the past 12 months, Masimo Corporation has had a low of $105.50 and a high of $198.00. As of last week, the company has a debt-to-equity ratio of 0.70, a current ratio of 2.10, and a quick ratio of 1.20. According to the stock market information, the enterprise value for the company is $6.83B, which is based on a 53.13 price-to-earnings ratio, a 4.46 price-to-earnings-growth ratio, and a beta of 0.81. The fifty day moving average price for MASI is $128.61 and a two-hundred day moving average price translates $156.35 for the stock.
The latest earnings results from Masimo Corporation (NASDAQ: MASI) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at $0.62, beating analysts’ expectations of $0.56 by 0.06. This compares to $0.33 EPS in the same period last year. The net profit margin was 5.30% and return on equity was 8.90% for MASI. The company reported revenue of $455.3 million for the quarter, compared to $565.3 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -19.46 percent. For the current quarter, analysts expect MASI to generate $498.85M in revenue.
Masimo Corporation(MASI) Company Profile
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
